Dr Thomas Soh is an oncologist practising at Gleneagles Hospital and Mount Elizabeth Novena Hospital, Singapore.
His subspecialty interests are in gastrointestinal cancer (oesophageal, gastric, colon and rectal cancer) and hepatobiliary cancer (liver, pancreas, bile duct and gall bladder cancer). He is also a cancer specialist who looks after patients with neuroendocrine cancers.
He was previously a consultant at the Department of Haematology-Oncology at National University Hospital (NUH) and a visiting consultant at Ng Teng Fong General Hospital.
Dr Soh was heavily involved in both undergraduate and postgraduate education, and was core faculty for both the Internal Medicine Residency programme and the Oncology Senior Residency programme at NUH from 2012 to 2016. He received the Teaching Excellence Award in 2014 from National University Cancer Institute (NCIS) and the Best Tutor Award in 2015 for undergraduate teaching by the University Medical Cluster at NUH.
Dr Soh believes in the delivery of quality healthcare, and was the lead and co-lead in several healthcare improvement projects. He received multiple awards for his involvement in the Clinical Practice Improvement Programmes he had implemented for NUH.
From 2013 – 2015, he contributed a leading role as honorary secretary of the executive committee of the Singapore Society of Oncology.
Dr Soh is actively involved in both research and education in cancer medicine. He had received funding for his work from the National Medical Research Council and received the Clinical Investigator Salary Support Program (CISSP) award 3 times. He had researched on drug response and toxicity in treating cancer, understanding how chemotherapy and targeted medication is absorbed and cleared in the body in relation to the pharmacokinetics and pharmacodynamics. He had published on genetic variants affecting chemotherapy in Asian breast cancer patients.
He was the principal investigator in several multicentre gastrointestinal cancer clinical trials and his research work has lead to more than 10 publications in high-impact medical and oncology journals. He was the principal investigator for studies of circulating tumour cells, and was also doing trials in hepatocellular cancer (hepatoma).
In advanced pancreatic cancer, he was principal investigator for studies using Gemcitabine, Masitinib and Abraxane.
Bachelor of Medicine, Bachelor of Surgery
Member of the Royal College of Physicians, UK